These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 28090024)

  • 21. Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis.
    Kunze K; Gamerdinger U; Leßig-Owlanj J; Sorokina M; Brobeil A; Tur MK; Blau W; Burchardt A; Käbisch A; Schliesser G; Kiehl M; Rosenwald A; Rummel M; Grimminger F; Hain T; Chakraborty T; Bräuninger A; Gattenlöhner S
    Pathol Res Pract; 2014 Jun; 210(6):369-76. PubMed ID: 24674452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
    Itzykson R; Kosmider O; Fenaux P
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
    Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
    Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clonal evolution in myelodysplastic syndromes].
    Yoshida K
    Rinsho Ketsueki; 2016 Jun; 57(6):723-9. PubMed ID: 27384851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q.
    Heuser M; Meggendorfer M; Cruz MM; Fabisch J; Klesse S; Köhler L; Göhring G; Ganster C; Shirneshan K; Gutermuth A; Cerny-Reiterer S; Krönke J; Panagiota V; Haferlach C; Koenecke C; Platzbecker U; Thiede C; Schroeder T; Kobbe G; Ehrlich S; Stamer K; Döhner K; Valent P; Schlegelberger B; Kroeger N; Ganser A; Haase D; Haferlach T; Thol F
    Leukemia; 2015 Sep; 29(9):1942-5. PubMed ID: 25792355
    [No Abstract]   [Full Text] [Related]  

  • 26. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.
    Mallo M; Del Rey M; Ibáñez M; Calasanz MJ; Arenillas L; Larráyoz MJ; Pedro C; Jerez A; Maciejewski J; Costa D; Nomdedeu M; Diez-Campelo M; Lumbreras E; González-Martínez T; Marugán I; Such E; Cervera J; Cigudosa JC; Alvarez S; Florensa L; Hernández JM; Solé F
    Br J Haematol; 2013 Jul; 162(1):74-86. PubMed ID: 23614682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
    Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q).
    Bello E; Pellagatti A; Shaw J; Mecucci C; Kušec R; Killick S; Giagounidis A; Raynaud S; Calasanz MJ; Fenaux P; Boultwood J
    Br J Haematol; 2015 Oct; 171(2):210-214. PubMed ID: 26085061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluorescence in situ hybridization testing for -5/5q, -7/7q, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study.
    Pitchford CW; Hettinga AC; Reichard KK
    Am J Clin Pathol; 2010 Feb; 133(2):260-4. PubMed ID: 20093235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Techniques and Gene Mutations in Myelodysplastic Syndromes.
    Mendoza H; Siddon AJ
    Clin Lab Med; 2023 Dec; 43(4):549-563. PubMed ID: 37865502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Diagnosis of MDS: morphology, chromosome abnormalities and genetic mutations].
    Hata T
    Rinsho Ketsueki; 2015 Oct; 56(10):1978-84. PubMed ID: 26458436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact.
    Bacher U; Haferlach T; Schnittger S; Zenger M; Meggendorfer M; Jeromin S; Roller A; Grossmann V; Krauth MT; Alpermann T; Kern W; Haferlach C
    Br J Haematol; 2014 Mar; 164(6):822-33. PubMed ID: 24372512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular and genetic features of myelodysplastic syndromes.
    Greenberg PL
    Int J Lab Hematol; 2012 Jun; 34(3):215-22. PubMed ID: 22212119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?
    Nazha A; Sekeres MA; Gore SD; Zeidan AM
    Oncologist; 2015 Sep; 20(9):1069-76. PubMed ID: 26194858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.
    Lai JL; Preudhomme C; Zandecki M; Flactif M; Vanrumbeke M; Lepelley P; Wattel E; Fenaux P
    Leukemia; 1995 Mar; 9(3):370-81. PubMed ID: 7885035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytogenetic place in managing myelodysplastic syndromes: an update by the Groupe francophone de cytogénétique hématologique (GFCH).
    Eclache V; Lafage-Pochitaloff M; Lefebvre C; Penther D; Raynaud S; Tigaud I
    Ann Biol Clin (Paris); 2016 Oct; 74(5):525-534. PubMed ID: 27546835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myelodysplastic syndrome with 5q deletion following IgM monoclonal gammopathy, showing gene mutation MYD88 L265P.
    Zagaria A; Coccaro N; Tota G; Anelli L; Minervini A; Casieri P; Cellamare A; Minervini CF; Brunetti C; Ricco A; Orsini P; Cumbo C; Specchia G; Albano F
    Blood Cells Mol Dis; 2015 Jan; 54(1):51-2. PubMed ID: 25159121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations.
    Aslan D; Garde C; Nygaard MK; Helbo AS; Dimopoulos K; Hansen JW; Severinsen MT; Treppendahl MB; Sjø LD; Grønbæk K; Kristensen LS
    Oncotarget; 2016 Mar; 7(9):9951-63. PubMed ID: 26848861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular pathophysiology of myelodysplastic syndromes.
    Lindsley RC; Ebert BL
    Annu Rev Pathol; 2013 Jan; 8():21-47. PubMed ID: 22934674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.